BR112015003033A2 - composto, composição farmacêutica e uso do composto - Google Patents

composto, composição farmacêutica e uso do composto

Info

Publication number
BR112015003033A2
BR112015003033A2 BR112015003033A BR112015003033A BR112015003033A2 BR 112015003033 A2 BR112015003033 A2 BR 112015003033A2 BR 112015003033 A BR112015003033 A BR 112015003033A BR 112015003033 A BR112015003033 A BR 112015003033A BR 112015003033 A2 BR112015003033 A2 BR 112015003033A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BR112015003033A
Other languages
English (en)
Other versions
BR112015003033B1 (pt
Inventor
Buron Frédéric
Guillaumet Gérald
Benedetti Hélène
Hiebel Marie-Aude
Routier Sylvain
Saurat Thibault
Original Assignee
Centre Nat Rech Scient
Univ Orleans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Orleans filed Critical Centre Nat Rech Scient
Publication of BR112015003033A2 publication Critical patent/BR112015003033A2/pt
Publication of BR112015003033B1 publication Critical patent/BR112015003033B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015003033-5A 2012-08-17 2013-08-16 Composto, composição farmacêutica e uso do composto BR112015003033B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1257856 2012-08-17
FR1257856A FR2994572B1 (fr) 2012-08-17 2012-08-17 Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique
PCT/EP2013/067129 WO2014027081A1 (fr) 2012-08-17 2013-08-16 Pyrido[3,2-d]pyrimidines trisubstituées, leurs procédés de préparation et leurs utilisations en thérapeutique

Publications (2)

Publication Number Publication Date
BR112015003033A2 true BR112015003033A2 (pt) 2017-08-08
BR112015003033B1 BR112015003033B1 (pt) 2022-11-16

Family

ID=47088936

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015003033-5A BR112015003033B1 (pt) 2012-08-17 2013-08-16 Composto, composição farmacêutica e uso do composto

Country Status (10)

Country Link
US (1) US10202372B2 (pt)
EP (1) EP2885297B1 (pt)
KR (1) KR20150046155A (pt)
CN (1) CN104718203A (pt)
AU (2) AU2013304046A1 (pt)
BR (1) BR112015003033B1 (pt)
CA (1) CA2881110A1 (pt)
ES (1) ES2655284T3 (pt)
FR (1) FR2994572B1 (pt)
WO (1) WO2014027081A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698587A (zh) * 2017-11-08 2018-02-16 贵州医科大学 杂环并嘧啶二酮类化合物制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0415367D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
US8232278B2 (en) 2005-06-24 2012-07-31 Gilead Sciences, Inc. Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C
JP2010501593A (ja) 2006-08-24 2010-01-21 セレネックス, インコーポレイテッド イソキノリン、キナゾリンおよびフタラジン誘導体
EA018708B1 (ru) * 2007-07-09 2013-10-30 Астразенека Аб ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
KR20120087808A (ko) * 2009-05-26 2012-08-07 엑셀리시스, 인코포레이티드 PI3K/m TOR의 억제제로서의 벤즈옥사제핀 및 이의 사용 및 제조 방법
CN102762565A (zh) * 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
FR2959510B1 (fr) * 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
WO2012058671A1 (en) * 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Substituted quinazoline and pyrido-pyrimidine derivatives

Also Published As

Publication number Publication date
AU2013304046A1 (en) 2015-02-26
FR2994572A1 (fr) 2014-02-21
CA2881110A1 (fr) 2014-02-20
US20150203489A1 (en) 2015-07-23
EP2885297A1 (fr) 2015-06-24
FR2994572B1 (fr) 2015-04-17
BR112015003033B1 (pt) 2022-11-16
AU2017272233A1 (en) 2018-01-04
KR20150046155A (ko) 2015-04-29
WO2014027081A1 (fr) 2014-02-20
ES2655284T3 (es) 2018-02-19
EP2885297B1 (fr) 2017-10-11
CN104718203A (zh) 2015-06-17
US10202372B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014029115A2 (pt) composto, composição farmacêutica, e, uso de um composto ou composição
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
BR112015002738A2 (pt) composto , e , composição farmacêutica
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112016003229A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014016635A8 (pt) composto, composição, e, uso de um composto
BR112013014644A2 (pt) composição farmacêutica e complexo
BR112014029642A2 (pt) composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 413/14

Ipc: C07D 413/14 (2006.01), C07D 471/04 (2006.01), A61P

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/08/2013, OBSERVADAS AS CONDICOES LEGAIS